Spheroids rapidly becoming a preferred 3D culture format

By Dr John Comley
Spring 2017
There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

By Dr Philip Dube
Spring 2017
Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and cli...

Monitoring the balance between immune repression and stimulation in cancer immunotherapy

By Dr Peter Schulz-Knappe and Dr Georg Lautscham
Spring 2017
Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies.

Fusion Therapy - a new approach to combining treatments

By Dr Thomas Mehrling
Fall 16
Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for n...

An Update on Hepatitis B Therapies

By Dr John Sullivan-Bolyai
Fall 16
The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant b...

Cell and gene therapies - the emerging fourth pillar of healthcare systems

By Keith Thompson
Fall 16
As the CEO of an organisation that deals exclusively in cell and gene therapies, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine a...

Ex Vivoverus in Vivo - the challenge of generating meaningful results with traditional cell culture

By Dr James Lim and Dr Fred Aswad
Summer 2016
While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results.

The Human Micobiome- a new frontier in drug discovery

By Lee Jones
Summer 2016
There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of hu...

Synthetic lethality and anti cancer drug discovery

By Jonathan D Moore
Spring 2016
Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

The role of immunodeficient animal models in advancing immuno-oncology research

By Dr Michael Seiler
Spring 2016
From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.

The Stem Cell Dilemma: reprogramming in-house versus off-the-shelf purchase of commerciallyproduced iPSC-derived cell types.

by Dr John Comley
Spring 16
The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenoty...

CAR-T : Looking beyond the hype.

By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann
Winter 2015/16
While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify cu...

The use of syngeneic models for the discovery of targets for combination therapy and predictive biomarkers of immunotherapy efficacy.

By Dr Jean- Pierre Wery
Winter 2015/16
Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initiall...

Valuation in portfolio management.

By Dr Michel Azoulay
Winter 2015/16
Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despit...

Human ES Cell Derived Functional Cells as Tools in Drug Discovery. Winter 2007

By Dr Petter Björquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner
Winter 2007
The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for the p...

Opportunities in Gastroenterology. Winter 2007

By Dirk Reyn
Winter 2007
Despite being one of the world’s largest therapeutic areas and presenting huge burdens to healthcare and economies globally, many of the diseases of the gastrointestinal (GI) tract are no...